{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:38:49Z","timestamp":1786441129840,"version":"build-2736575974"},"reference-count":96,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathophysiology"],"abstract":"<jats:p>Introduction: Bispecific antibodies (BsAbs) are a promising and potent therapeutic intervention for relapsed or refractory (R\/R) hematologic malignancies, including acute lymphoblastic leukemia (ALL), multiple myeloma (MM), and B-cell lymphomas. These recombinant molecules are designed to target two distinct antigens or epitopes. While BsAbs have shown significant efficacy in managing hematologic malignancies, toxicities must be carefully monitored and their safety profiles require further investigation. This meta-analysis investigates cardiovascular adverse effects associated with seven BsAbs across multiple clinical trials. Methods: A systematic literature review identified seven BsAbs, blinatumomab, elranatamab, epcoritamab, glofitamab, mosunetuzumab, talquetamab, and teclistamab, analyzing 25 clinical trials (Phase I\u2013III) that included monotherapy regimens. The cardiovascular adverse events studied were arrhythmias, heart failure, blood pressure changes, and myocardial infarctions. A meta-analysis using the R meta package calculated proportions and 95% confidence intervals (CIs) and employed a random-effects model to assess heterogeneity. Results: Among 3215 patients, pooled analysis revealed significant findings with 13.6% cardiac arrhythmia (95% CI 10.1\u201318.2%, p = 0.05), 13.3% hypotension (95% CI 10\u201317.3%, p &lt; 0.0001), 10.2% tachycardia (95% CI 7.6\u201313.5%, p = 0.0003), and 3.4% sudden death (95% CI 0\u201380%, p = 0.046). Less frequent events were hypertension (8%), acute myocardial infarction (1.5%), heart failure (1.4%), and atrial fibrillation (1.3%). Discussion: As BsAbs see increased use in R\/R hematologic malignancies, cardiovascular complications must be closely monitored. This analysis highlights hypotension, cardiac arrhythmias, tachycardia, and sudden death as significant adverse effects. Although study heterogeneity and limited patient-level data may have influenced incidence estimates, these findings support routine cardiovascular monitoring and underscore the need for prospective studies to identify high-risk patients and optimize prevention and management strategies. Oncologists, cardiologists, and pharmacists should establish strategies for early detection and management to optimize patients\u2019 outcomes.<\/jats:p>","DOI":"10.3390\/pathophysiology33030060","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:09:36Z","timestamp":1786435776000},"page":"60","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6461-5560","authenticated-orcid":false,"given":"Derek","family":"Tai","sequence":"first","affiliation":[{"name":"Department of Medicine, Loma Linda University Medical Center, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Medicine, University California San Francisco Fresno, Fresno, CA 93701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9038-8752","authenticated-orcid":false,"given":"Aren","family":"Dermarderosian","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norayr","family":"Mkrtchyan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California Davis, Sacramento, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Harbor-UCLA Medical Center, Torrance, CA 90502, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinisha","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Loma Linda University Medical Center, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Science, University of California, La Jolla, San Diego, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Akhtari","sequence":"additional","affiliation":[{"name":"Division of Transplant, Cellular Therapy and Hematologic Malignancies, Loma Linda University Cancer Center, 11234 Anderson St, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. 4","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete Hematologic and Molecular Response in Adult Patients with Relapsed\/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2018-99-117507","article-title":"Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia","volume":"132","author":"Aboudalle","year":"2018","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7650","DOI":"10.1002\/cam4.2680","article-title":"Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage","volume":"8","author":"Yoon","year":"2019","journal-title":"Cancer Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-018-3495-2","article-title":"Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed\/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party","volume":"98","author":"Jung","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/16078454.2022.2111992","article-title":"Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study","volume":"27","author":"Zhou","year":"2022","journal-title":"Hematology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/cas.14322","article-title":"Phase 1b\/2 study of blinatumomab in Japanese adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2021.06.005","article-title":"Relationship of T- and B-cell kinetics to clinical response in patients with relapsed\/refractory non-Hodgkin lymphoma treated with blinatumomab","volume":"100","author":"Zugmaier","year":"2021","journal-title":"Exp. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1002\/cam4.3731","article-title":"Blinatumomab as first salvage versus second or later salvage in adults with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis","volume":"10","author":"Topp","year":"2021","journal-title":"Cancer Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20363613231207483","DOI":"10.1177\/20363613231207483","article-title":"Elrexfio\u2122 (elranatamab-bcmm): The game-changer in treatment of multiple myeloma","volume":"15","author":"Rais","year":"2023","journal-title":"Rare Tumors"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/bjh.19346","article-title":"Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3","volume":"204","author":"Mohty","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"Hemasphere"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/jjco\/hyae068","article-title":"Elranatamab in Japanese patients with relapsed\/refractory multiple myeloma: Results from MagnetisMM-2 and MagnetisMM-3","volume":"54","author":"Iida","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: A national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1111\/cas.15996","article-title":"Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B-cell lymphoma","volume":"114","author":"Izutsu","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.clml.2023.11.005","article-title":"Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated with Epcoritamab","volume":"24","author":"Phillips","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-023-01488-4","article-title":"CD20 \u00d7 CD3 bispecific antibodies for lymphoma therapy: Latest updates from ASCO 2023 annual meeting","volume":"16","author":"Liu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1254\/fpj.23076","article-title":"Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly\u00ae subcutaneous injection) for malignant lymphoma","volume":"159","author":"Takaura","year":"2024","journal-title":"Nihon Yakurigaku Zasshi. Folia Pharmacol. Jpn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjh.18519","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study","volume":"202","author":"Hess","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.2147\/CMAR.S267258","article-title":"Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma","volume":"13","author":"Ollila","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2321648","DOI":"10.1080\/2162402X.2024.2321648","article-title":"Trial watch: Bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma","volume":"13","author":"Cassanello","year":"2024","journal-title":"Oncoimmunology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mih\u00e1lyov\u00e1, J., Hradsk\u00e1, K., Jel\u00ednek, T., Motais, B., Celichowski, P., and H\u00e1jek, R. (2021). Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111470"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Saleh, K., Khoury, R., Khalife, N., Chahine, C., Ibrahim, R., Tikriti, Z., and Le Cesne, A. (2024). The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. J. Pers. Med., 14.","DOI":"10.3390\/jpm14070666"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"McIlroy, G., Lax, S., Gaskell, C., Jackson, A., Rhodes, M., Seale, T., Fox, S., Hopkins, L., Okosun, J., and Barrington, S.F. (2024). Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): Study protocol for a multi-centre, open-label, randomised, phase II platform trial. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12112-0"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: Updated dose escalation data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","article-title":"Glofitamab CD20-TCB bispecific antibody","volume":"62","author":"Minson","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","article-title":"Glofitamab: First Approval","volume":"83","author":"Shirley","year":"2023","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Rentsch, V., Seipel, K., Banz, Y., Wiedemann, G., Porret, N., Bacher, U., and Pabst, T. (2022). Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. Cancers, 14.","DOI":"10.3390\/cancers14102516"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hon.3174","article-title":"Glofitamab in relapsed\/refractory diffuse large B-cell lymphoma: Real-world data","volume":"41","author":"Gulbas","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17474086.2023.2285978","article-title":"Dual target dilemma: Navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma","volume":"16","author":"Davis","year":"2023","journal-title":"Expert. Rev. Hematol."},{"key":"ref_42","first-page":"1269","article-title":"Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma","volume":"109","author":"Song","year":"2024","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-023-01420-w","article-title":"Glofitamab therapy for diffuse large B cell lymphoma: Latest updates from the 2022 ASH Annual Meeting","volume":"16","author":"Wang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41571-022-00725-y","article-title":"Engaging results with glofitamab in DLBCL","volume":"20","author":"Killock","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/cncr.35217","article-title":"Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan","volume":"130","author":"Hsu","year":"2024","journal-title":"Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Barca, E.G. (2022). Role of Bispecific Antibodies in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in the CART Era. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.909008"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2023011089","article-title":"Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma","volume":"8","author":"Gritti","year":"2024","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.clml.2024.05.010","article-title":"SOHO State of the Art Updates and Next Questions|Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma","volume":"24","author":"Bennett","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jcyt.2024.05.002","article-title":"Allogeneic transplantation after immunotherapy for relapsed\/refractory non-Hodgkin lymphoma: A comparison with a historical cohort","volume":"26","author":"Mariotti","year":"2024","journal-title":"Cytotherapy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2023-174081","article-title":"Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study","volume":"142","author":"Topp","year":"2023","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/bjh.19057","article-title":"Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas","volume":"204","author":"Dodero","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: First Approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-023-01462-0","article-title":"Mosunetuzumab and lymphoma: Latest updates from 2022 ASH annual meeting","volume":"16","author":"Cao","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: Safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab Safety Profile in Patients with Relapsed\/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I\/II Trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: Impact of translational system modeling","volume":"6","author":"Hosseini","year":"2020","journal-title":"NPJ Syst. Biol. Appl."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable Responses with Mosunetuzumab in Relapsed\/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I\/II Study","volume":"42","author":"Budde","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: A phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clml.2023.09.007","article-title":"Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed\/Refractory Follicular Lymphoma","volume":"24","author":"Bosch","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CMAR.S381493","article-title":"Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab","volume":"15","author":"Lopedote","year":"2023","journal-title":"Cancer Manag. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Sanz","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/cncr.34810","article-title":"FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma","volume":"129","author":"Nierengarten","year":"2023","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jjco\/hyad082","article-title":"Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"53","author":"Munakata","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ray, M.D., Kanters, S., Beygi, S., Best, T., Wulff, J., Limbrick-Oldfield, E., Patel, A.R., and Oluwole, O.O. (2024). Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed\/Refractory Follicular Lymphoma. Transpl. Cell Ther., 30.","DOI":"10.1016\/j.jtct.2024.06.016"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"101099","DOI":"10.1016\/j.blre.2023.101099","article-title":"Thinking \u201coutside the germinal center\u201d: Re-educating T cells to combat follicular lymphoma","volume":"61","author":"Kambhampati","year":"2023","journal-title":"Blood Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1002\/cncr.34483","article-title":"Top advances in lymphoma for 2021","volume":"128","author":"Patel","year":"2022","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Jacobs, R., and Jacobson, C. (2024). The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1384600"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1182\/blood-2023-189151","article-title":"Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed\/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1\/2 MonumenTAL-1 Study","volume":"142","author":"Schinke","year":"2023","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S561","DOI":"10.1016\/S2152-2650(24)01689-6","article-title":"MM-492 Long-term Efficacy and Safety Results From the Phase 1\/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D\u00d7CD3 Bispecific Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"24","author":"Rasche","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2021-146868","article-title":"Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D \u00d7 CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Krishnan","year":"2021","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated Results of Talquetamab, a GPRC5D\u00d7CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1\/2 MonumenTAL-1 Study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2023-181228","article-title":"Efficacy and Safety of Less Frequent\/Lower Intensity Dosing of Talquetamab in Patients with Relapsed\/Refractory Multiple Myeloma: Results from the Phase 1\/2 MonumenTAL-1 Study","volume":"142","author":"Chari","year":"2023","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2021.39.15_suppl.8007","article-title":"Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (MM)","volume":"39","author":"Krishnan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2022.40.16_suppl.8007","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1","volume":"40","author":"Nooka","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Moreau","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Dima, D., Davis, J.A., Ahmed, N., Jia, X., Sannareddy, A., Shaikh, H., Shune, L., Kaur, G., Khouri, J., and Afrough, A. (2024). Safety and Efficacy of Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: A Real-World Experience. Transpl. Cell Ther., 30.","DOI":"10.1016\/j.jtct.2023.12.537"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1182\/blood-2023-183085","article-title":"Teclistamab in Relapsed\/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest","volume":"142","author":"Stepanovic","year":"2023","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Omer, M.H., Shafqat, A., Ahmad, O., Alkattan, K., Yaqinuddin, A., and Damlaj, M. (2023). Bispecific Antibodies in Hematological Malignancies: A Scoping Review. Cancers, 15.","DOI":"10.3390\/cancers15184550"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"Zweegman","year":"2023","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/10428194.2022.2064981","article-title":"Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL","volume":"63","author":"Katz","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood-2021-152822","article-title":"A Phase1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed\/Refractory (R\/R) Indolent Non Hodgkin\u2019s Lymphoma (NHL)","volume":"138","author":"Rossi","year":"2021","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1159\/000525835","article-title":"Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed\/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort","volume":"145","author":"Goto","year":"2022","journal-title":"Acta Haematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Pathophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1873-149X\/33\/3\/60\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:17:59Z","timestamp":1786439879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1873-149X\/33\/3\/60"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":96,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pathophysiology33030060"],"URL":"https:\/\/doi.org\/10.3390\/pathophysiology33030060","relation":{},"ISSN":["1873-149X"],"issn-type":[{"value":"1873-149X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}